Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NVCT
#3038
Nuvectis Pharma, Inc. Common Stock
8.8
6
-0.78%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
-0.78%
Mudança mensal
+0.68%
Mudança em 6 meses
+32.24%
Mudança anual
+27.85%
Fechamento anterior
8.9
3
Open
8.8
6
Bid
Ask
Low
8.8
6
High
8.8
6
Volume
17
Mercados
Ações
Cuidados de saúde
NVCT
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
14.75 M
17.77 M
23.39 M
26.49 M
—
Valuation ratios
Enterprise value
90.64 M
128.2 M
108.05 M
168.41 M
651.59 M
Price to earnings ratio
-4.97
-5.8
-4.87
-5.72
-25.14
Price to sales ratio
—
—
—
—
—
Price to cash flow ratio
7
8.08
7.56
10.29
44.81
Price to book ratio
6.68
10.57
9.53
8.94
16.39
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.94
1.16
1.02
0.83
0.85
Return on equity %
1.34
1.82
1.96
1.44
1.34
Return on invested capital %
—
—
—
—
—
Gross margin %
—
—
—
—
—
Operating margin %
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
Net margin %
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
3.3
2.75
2.09
2.38
11.4
Inventory turnover
—
—
—
—
—
Asset turnover
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.07
1.03
0.72
0.73
0.75
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
1.58
1.23
1.08
1.45
5.76
Net current asset value per share
1.61
1.23
1.09
1.45
5.8
Tangible book value per share
1.12
0.78
0.57
0.84
3.74
Working capital per share
1.12
0.78
0.57
0.84
3.74
Book value per share
1.12
0.78
0.57
0.84
3.74
Notícias
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib
H.C. Wainwright mantém recomendação de compra para ações da Nuvectis Pharma
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright
Kaplan compra ações da Nuvectis Pharma (NVCT) no valor de US$ 64.240
Presidente da Nuvectis Pharma, Bentsur, compra ações no valor de US$ 28.600
Diretor da Nuvectis Pharma, Sanchez, compra US$ 75 mil em ações NVCT
H.C. Wainwright mantém recomendação de compra para Nuvectis Pharma com preço-alvo de US$ 10
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target
Nuvectis Pharma adds former Intra-Cellular exec to board of directors
Nuvectis initiates phase 1b program for cancer drug NXP900
Nuvectis (NVCT) Q2 Loss Widens 43%
Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright